Literature DB >> 12873483

4-Phenyl-4H-pyrans as IK(Ca) channel blockers.

Klaus Urbahns1, Ervin Horváth, Johannes Peter Stasch, Frank Mauler.   

Abstract

4-Phenyl-4H-pyrans have been identified as potent and specific IK(Ca) channel blockers. Their synthesis and structure-activity relationships are described. A selected derivative, rac-11, reduces the infarct volume in a rat subdural hematoma model of traumatic brain injury after iv administration.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12873483     DOI： 10.1016/s0960-894x(03)00560-2

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  15 in total

Review 1.  K+ channels as targets for specific immunomodulation.

Authors:  K George Chandy; Heike Wulff; Christine Beeton; Michael Pennington; George A Gutman; Michael D Cahalan
Journal:  Trends Pharmacol Sci       Date:  2004-05       Impact factor: 14.819

Review 2.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

3.  Functional KCa3.1 K+ channels are required for human lung mast cell migration.

Authors:  G Cruse; S M Duffy; C E Brightling; P Bradding
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

4.  Therapeutic potential of KCa3.1 blockers: recent advances and promising trends.

Authors:  Heike Wulff; Neil A Castle
Journal:  Expert Rev Clin Pharmacol       Date:  2010-05       Impact factor: 5.045

5.  NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease.

Authors:  D Strøbæk; D T Brown; D P Jenkins; Y-J Chen; N Coleman; Y Ando; P Chiu; S Jørgensen; J Demnitz; H Wulff; P Christophersen
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

6.  Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore.

Authors:  Hai M Nguyen; Vikrant Singh; Brandon Pressly; David Paul Jenkins; Heike Wulff; Vladimir Yarov-Yarovoy
Journal:  Mol Pharmacol       Date:  2017-01-26       Impact factor: 4.436

Review 7.  Critical regulation of atherosclerosis by the KCa3.1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis.

Authors:  Yan-Rong Zhu; Xiao-Xin Jiang; Dai-Min Zhang
Journal:  J Mol Med (Berl)       Date:  2019-06-28       Impact factor: 4.599

Review 8.  Trafficking of intermediate (KCa3.1) and small (KCa2.x) conductance, Ca(2+)-activated K(+) channels: a novel target for medicinal chemistry efforts?

Authors:  Corina M Balut; Kirk L Hamilton; Daniel C Devor
Journal:  ChemMedChem       Date:  2012-08-07       Impact factor: 3.466

9.  Expression and Role of the Intermediate-Conductance Calcium-Activated Potassium Channel KCa3.1 in Glioblastoma.

Authors:  Luigi Catacuzzeno; Bernard Fioretti; Fabio Franciolini
Journal:  J Signal Transduct       Date:  2012-05-17

10.  KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.

Authors:  Brandon M Brown; Brandon Pressley; Heike Wulff
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.